DBP B Stock Overview
Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Double Bond Pharmaceutical International AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.77 |
52 Week High | kr2.00 |
52 Week Low | kr0.25 |
Beta | 0.68 |
1 Month Change | 9.40% |
3 Month Change | -4.00% |
1 Year Change | -3.76% |
3 Year Change | -63.25% |
5 Year Change | -86.71% |
Change since IPO | -82.93% |
Recent News & Updates
Recent updates
Shareholder Returns
DBP B | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | 10.0% | 3.0% | 1.9% |
1Y | -3.8% | 81.6% | 17.1% |
Return vs Industry: DBP B underperformed the Swedish Pharmaceuticals industry which returned 85.9% over the past year.
Return vs Market: DBP B underperformed the Swedish Market which returned 19% over the past year.
Price Volatility
DBP B volatility | |
---|---|
DBP B Average Weekly Movement | 15.4% |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in SE Market | 12.9% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: DBP B's share price has been volatile over the past 3 months.
Volatility Over Time: DBP B's weekly volatility has decreased from 21% to 15% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 10 | Igor Lokot | https://www.doublebp.com |
Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases. It offers Temodex, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. The company is also developing Belopenem for the treatment of bacterial pneumonia.
Double Bond Pharmaceutical International AB (publ) Fundamentals Summary
DBP B fundamental statistics | |
---|---|
Market cap | kr78.36m |
Earnings (TTM) | -kr17.34m |
Revenue (TTM) | kr1.37m |
57.2x
P/S Ratio-4.5x
P/E RatioIs DBP B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DBP B income statement (TTM) | |
---|---|
Revenue | kr1.37m |
Cost of Revenue | kr4.68m |
Gross Profit | -kr3.31m |
Other Expenses | kr14.03m |
Earnings | -kr17.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.17 |
Gross Margin | -241.22% |
Net Profit Margin | -1,265.24% |
Debt/Equity Ratio | 0% |
How did DBP B perform over the long term?
See historical performance and comparison